Results 81 to 90 of about 48,812 (228)

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

Allergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan, Sofia Vlasova, Alicia Chenoweth, Debra H. Josephs, Heather J. Bax, Sophia N. Karagiannis   +5 more
wiley   +1 more source

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma

, 2012
Claire VerschraegenProfessor of Medicine, Division of Hematology Oncology, University of Vermont, Vermont Cancer Center, VT, USABackground: Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor ...
Verschraegen C
core  

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Journal for ImmunoTherapy of Cancer, 2019
Purpose To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases.
Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile, Vincenzo Esposito   +9 more
doaj   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source

Real-world impact of education: treating patients with ipilimumab in a community practice setting

, 2013
Blanca Ledezma,1 Annie Heng2 1Department of Hematology and Oncology, University of California, Los Angeles, Santa Monica, CA, USA; 2Angeles Clinic and Research Institute, Los Angeles, CA, USA Abstract: After decades without promising new treatments for ...
Heng A, Ledezma B
core  

Ipilimumab-induced colitis on FDG PET/CT.

, 2012
A 52-year-old woman with metastatic melanoma was treated with ipilimumab. After 2 cycles of treatment, she developed watery diarrhea, sweats, and chills.
Carvajal, Richard D, Vargas, Herbert Alberto, Lyall, Ashima, MD, Ulaner, Gary   +3 more
core   +1 more source

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Case Reports in Oncology, 2018
Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies.
Yoshito Nishimura, Miho Yasuda, Kazuki Ocho, Masaya Iwamuro, Osamu Yamasaki, Takehiro Tanaka, Fumio Otsuka   +6 more
doaj   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)

The article by Diab et al entitled “Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)” (Journal of Clinical Oncology 10.1200/JCO ...
Dalle, Stephane, Leccia, Marie-Therese, Chunduru, Srinivas, Arenberger, Petr, Krajsova, Ivana, Walker, John W. T., Kapiteijn, Ellen, Guidoboni, Massimo, Butler, Marcus O., In, Gino K., Negrier, Sylvie, Maio, Michele, Loquai, Carmen, Lebbe, Celeste, Robert, Caroline, Abdel-Wahab, Reham, Rahimian, Shahram, Mortier, Laurent, Grob, Jean-Jacques, Guida, Michele, Diab, Adi, Ascierto, Paolo A., Haferkamp, Sebastian, Cruz-Merino, Luis de la, Atkinson, Victoria   +24 more
core   +1 more source

Circumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes

Brain Pathology, EarlyView.
In this study including 31 circumscribed meningeal melanocytic neoplasms (melanocytoma, intermediate‐grade melanocytic tumor [IMT], and melanoma), overall survival (OS) differed significantly among the groups, with melanoma showing significantly worse OS than melanocytoma and IMT showing intermediate OS between melanocytoma and melanoma.
Yi Zhu, Nishika Karbhari, Timothy J. Kaufmann, Aditya Raghunathan, Cristiane M. Ida, Cinthya J. Zepeda‐Mendoza, Ian J. Dryden, Shahriar Salamat, Chathu Atherton, Sarah M. Jenkins, Svetomir N. Markovic, Ugur T. Sener, Caterina Giannini   +12 more
wiley   +1 more source